A collection of clinical trials addressing the potential benefits of raloxifene (Evista®) in the primary and secondary prevention of osteoporosis in end-stage renal disease patients.

***Note: Comments about this teaching resource, its content, and your thoughts can be made on this website (by registered users) or on Facebook (all users).


Time Required (estimated): 60 minutes

Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International 2003, Volume 63, pp. 2269–2274 (article)

The effects of raloxifene on bone turnover markers and bone mineral density in women on maintenance hemodialysis. Clinical and Experimental Nephrology 2010 Nov 11. (article)

Raloxifene ameliorates progressive bone loss in postmenopausal dialysis patients with controlled parathyroid hormone levels. Clinical Nephrology 2009 Volume 72, pp. 423-9. (article)

Recommend to a Colleague/Friend
Was this teaching resource valuable? Scroll down and complete our 6-point Transparent Peer Evaluation.

Transparent Peer Review
Your reviews are anonymous

[starratingmulti id=”3″]

To learn more about our 6-point transparent peer review system, click here



You must be logged in to post a comment.




Speak your mind

  • Nephrology On-Demand Plus

    Our full-featured iOS app for the iPhone and iPad. NOD + integrates
    1. kidney education,
    2. training, and
    3. recruitment

    into a streamlined and user-friendly interface.


  • Kidney Konnection

    A newsletter that discusses sophisticated topics in Nephrology for physicians in Internal Medicine.
    Click here to access your complimentary subscription